Indaptus Therapeutics Key Executives
This section highlights Indaptus Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Indaptus Therapeutics
(Showing 0 of )
Indaptus Therapeutics Earnings
This section highlights Indaptus Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Indaptus Therapeutics, Inc., a pre-clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical oncology candidate is Decoy20 to single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as hepatitis B virus and human immunodeficiency virus infection, which is in Phase I clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. was incorporated in 2021 and is headquartered in New York, New York.
$0.47
Stock Price
$6.78M
Market Cap
7
Employees
New York, NY
Location
Financial Statements
Access annual & quarterly financial statements for Indaptus Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $1.28K | $1.78K | $1.40K | $852 |
| Gross Profit | $- | $-1.28K | $-1.78K | $-1.40K | $-852 |
| Gross Profit Ratio | 0.00% | - | - | - | - |
| Research and Development Expenses | $7.25M | $7.62M | $6.32M | $2.52M | $2.66M |
| General and Administrative Expenses | $8.11M | $8.66M | $8.59M | $5.21M | $944.25K |
| Selling and Marketing Expenses | $- | $100.74K | $- | $- | $- |
| Selling General and Administrative Expenses | $8.11M | $8.76M | $8.59M | $5.21M | $944.25K |
| Other Expenses | $- | $- | $- | $- | $- |
| Operating Expenses | $15.37M | $16.38M | $14.91M | $7.73M | $3.60M |
| Cost and Expenses | $- | $16.38M | $14.91M | $7.73M | $3.60M |
| Interest Income | $- | $- | $588.11K | $17.72K | $15.11K |
| Interest Expense | $- | $- | $588.11K | $- | $- |
| Depreciation and Amortization | $- | $1.28K | $1.78K | $1.40K | $852 |
| EBITDA | $-15.37M | $-16.38M | $-14.91M | $-7.73M | $-3.60M |
| EBITDA Ratio | - | - | - | - | - |
| Operating Income | $-15.37M | $-16.38M | $-14.91M | $-7.73M | $-3.60M |
| Operating Income Ratio | - | - | - | - | - |
| Total Other Income Expenses Net | $343.72K | $955.00K | $588.11K | $17.72K | $15.11K |
| Income Before Tax | $-15.02M | $-15.42M | $-14.32M | $-7.71M | $-3.58M |
| Income Before Tax Ratio | - | - | - | - | - |
| Income Tax Expense | $- | $- | $-588.11K | $-17.72K | $-15.11K |
| Net Income | $-15.02M | $-15.42M | $-13.73M | $-7.69M | $-3.57M |
| Net Income Ratio | - | - | - | - | - |
| EPS | $-1.61 | $-1.84 | $-1.66 | $-1.88 | $-7.34 |
| EPS Diluted | $-1.61 | $-1.84 | $-1.66 | $-1.88 | $-7.34 |
| Weighted Average Shares Outstanding | 9.36M | 8.40M | 8.26M | 4.09M | 486.17K |
| Weighted Average Shares Outstanding Diluted | 9.36M | 8.40M | 8.26M | 4.09M | 486.17K |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $1.93K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $-735 | $- | $- | $735 | $320 | $321 | $322 | $321 | $321 | $392 | $534 | $534 | $535 | $- | $7.38M | $4.18M | $- | $- | $- | $- |
| Gross Profit | $735 | $- | $- | $-735 | $1.61K | $-321 | $-322 | $-321 | $-321 | $-392 | $-534 | $-534 | $-535 | $- | $-7.38M | $-4.18M | $- | $- | $- | $- |
| Gross Profit Ratio | - | 0.00% | 0.00% | - | 83.40% | - | - | - | - | - | - | - | - | - | - | - | 0.00% | - | - | - |
| Research and Development Expenses | $2.48M | $1.47M | $1.71M | $1.59M | $2.03M | $2.23M | $1.48M | $1.88M | $1.91M | $1.61M | $1.51M | $1.30M | $944.64K | $697.67K | $1.81M | $489.72K | $352.13K | $1.35M | $1.27M | $374.44K |
| General and Administrative Expenses | $1.69M | $1.68M | $2.39M | $2.35M | $2.15M | $2.02M | $2.01M | $2.58M | $2.18M | $1.94M | $2.36M | $2.10M | $2.27M | $2.67M | $2.39M | $124.25K | $416.42K | $196.58K | $1.63M | $184.94K |
| Selling and Marketing Expenses | $735 | $- | $- | $-735 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $9.18K |
| Selling General and Administrative Expenses | $1.69M | $1.68M | $2.39M | $2.35M | $2.15M | $2.02M | $2.01M | $2.58M | $2.18M | $1.94M | $2.36M | $2.10M | $2.27M | $2.67M | $2.39M | $124.25K | $416.42K | $196.58K | $1.63M | $194.12K |
| Other Expenses | $-136.56K | $- | $- | $136.56K | $2.03M | $326.02K | $250.20K | $201.93K | $- | $86.18K | $33.76K | $36.92K | $- | $827 | $- | $1.55K | $- | $3.68K | $- | $- |
| Operating Expenses | $4.17M | $3.14M | $4.11M | $3.94M | $4.18M | $4.25M | $3.50M | $4.46M | $4.09M | $3.55M | $3.87M | $3.40M | $3.22M | $3.37M | $4.19M | $613.98K | $768.55K | $1.55M | $2.90M | $558.58K |
| Cost and Expenses | $-11.19M | $3.14M | $4.11M | $3.94M | $4.18M | $4.25M | $3.50M | $4.46M | $4.09M | $3.55M | $3.87M | $3.40M | $3.22M | $3.37M | $4.19M | $613.98K | $768.55K | $1.55M | $2.90M | $558.58K |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $827 | $- | $- | $- | $3.68K | $- | $- |
| Interest Expense | $- | $- | $- | $- | $201.93K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $4.00K | $- |
| Depreciation and Amortization | $-735 | $- | $- | $735 | $320 | $321 | $322 | $321 | $321 | $392 | $534 | $534 | $535 | $-1.18M | $652.00K | $526.00K | $213 | $-610.36K | $213 | $213 |
| EBITDA | $-4.17M | $-3.14M | $-4.11M | $-3.94M | $-4.18M | $-4.25M | $-3.49M | $-4.45M | $-4.09M | $-3.55M | $-3.87M | $-3.40M | $-3.22M | $-3.37M | $-528.43K | $-613.76K | $-768.34K | $-1.55M | $-2.60M | $-568.35K |
| EBITDA Ratio | - | - | - | - | -216769.40% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Income | $-4.17M | $-3.14M | $-4.11M | $-3.94M | $-4.18M | $-4.25M | $-3.50M | $-4.46M | $-4.09M | $-3.55M | $-3.87M | $-3.40M | $-3.22M | $-3.37M | $-7.38M | $-613.98K | $-768.55K | $-1.55M | $-2.90M | $-568.56K |
| Operating Income Ratio | - | - | - | - | -216786.00% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Total Other Income Expenses Net | $40.52K | $73.02K | $93.62K | $136.56K | $176.85K | $326.02K | $250.20K | $201.93K | $431.25K | $86.18K | $33.76K | $36.92K | $2.17K | $827 | $-6.89M | $1.55K | $-1.67K | $3.68K | $4.00K | $9.98K |
| Income Before Tax | $-4.13M | $-3.07M | $-4.02M | $-3.81M | $-4.00M | $-3.92M | $-3.25M | $-4.25M | $-3.66M | $-3.47M | $-3.84M | $-3.37M | $-3.22M | $-3.37M | $-7.42M | $-612.42K | $-770.22K | $-1.54M | $-2.90M | $-558.58K |
| Income Before Tax Ratio | - | - | - | - | -207613.02% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Income Tax Expense | $-4 | $- | $- | $4 | $-4.18M | $39.91K | $-121.76K | $-201.93K | $-431.25K | $-86.18K | $- | $-36.92K | $-13.00K | $1.18M | $13.00K | $20.00K | $- | $610.36K | $46.00K | $- |
| Net Income | $-4.13M | $-3.07M | $-4.02M | $-3.81M | $-4.00M | $-3.92M | $-3.25M | $-4.05M | $-3.22M | $-3.38M | $-3.84M | $-3.33M | $-3.22M | $-3.37M | $-7.43M | $-612.42K | $-770.22K | $-1.54M | $-2.95M | $-558.58K |
| Net Income Ratio | - | - | - | - | -207613.02% | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS | $-0.37 | $-0.32 | $-0.47 | $-0.45 | $-0.48 | $-0.47 | $-0.39 | $-0.48 | $-0.39 | $-0.41 | $-0.46 | $-0.40 | $-0.80 | $-0.81 | $-1.37 | $-0.11 | $-0.14 | $-0.29 | $-0.55 | $-0.76 |
| EPS Diluted | $-0.37 | $-0.32 | $-0.47 | $-0.45 | $-0.48 | $-0.47 | $-0.39 | $-0.48 | $-0.39 | $-0.41 | $-0.46 | $-0.40 | $-0.80 | $-0.81 | $-1.37 | $-0.11 | $-0.14 | $-0.29 | $-0.55 | $-0.76 |
| Weighted Average Shares Outstanding | 9.36M | 9.51M | 8.54M | 8.44M | 8.40M | 8.40M | 8.40M | 8.40M | 8.27M | 8.26M | 8.26M | 8.26M | 4.09M | 4.18M | 5.41M | 5.41M | 5.41M | 5.41M | 5.41M | 732.00K |
| Weighted Average Shares Outstanding Diluted | 9.36M | 9.51M | 8.54M | 8.44M | 8.40M | 8.40M | 8.40M | 8.40M | 8.27M | 8.26M | 8.26M | 8.26M | 4.09M | 4.18M | 5.41M | 5.41M | 5.41M | 5.41M | 5.41M | 732.63K |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $5.79M | $13.36M | $9.63M | $39.13M | $1.64M |
| Short Term Investments | $- | $- | $16.81M | $- | $- |
| Cash and Short Term Investments | $5.79M | $13.36M | $26.43M | $39.13M | $1.64M |
| Net Receivables | $- | $- | $- | $21.06K | $- |
| Inventory | $- | $- | $- | $- | $- |
| Other Current Assets | $831.58K | $633.16K | $892.34K | $1.23M | $94.50K |
| Total Current Assets | $6.62M | $14.00M | $27.24M | $40.39M | $1.73M |
| Property Plant Equipment Net | $82.17K | $173.94K | $81.31K | $172.89K | $1.35K |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $638.25K | $754.73K | $738.25K | $16.48K | $44.45K |
| Total Non-Current Assets | $720.43K | $928.67K | $819.56K | $189.37K | $45.79K |
| Other Assets | $- | $- | $0 | $-0 | $- |
| Total Assets | $7.34M | $14.92M | $28.06M | $40.58M | $1.78M |
| Account Payables | $870.23K | $806.00K | $1.38M | $2.54M | $155.96K |
| Short Term Debt | $84.16K | $101.70K | $160.99K | $96.47K | $- |
| Tax Payables | $- | $40.00K | $128.93K | $97.72K | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $2.44M | $1.83M | $1.77M | $1.87M | $1.86M |
| Total Current Liabilities | $3.39M | $2.77M | $3.43M | $4.60M | $2.02M |
| Long Term Debt | $- | $73.35K | $- | $72.86K | $- |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $- | $73.35K | $1.46M | $72.86K | $- |
| Other Liabilities | $- | $- | $-1.46M | $- | $- |
| Total Liabilities | $3.39M | $2.85M | $3.43M | $4.68M | $2.02M |
| Preferred Stock | $- | $- | $- | $- | $8.36K |
| Common Stock | $120.14K | $84.01K | $84.01K | $82.59K | $19.45K |
| Retained Earnings | $-60.44M | $-45.42M | $-29.99M | $-15.67M | $-7.96M |
| Accumulated Other Comprehensive Income Loss | $- | $-0 | $96.43K | $- | $- |
| Other Total Stockholders Equity | $64.26M | $57.41M | $54.44M | $51.49M | $7.69M |
| Total Stockholders Equity | $3.94M | $12.08M | $24.63M | $35.90M | $-237.70K |
| Total Equity | $3.94M | $12.08M | $24.63M | $35.90M | $-237.70K |
| Total Liabilities and Stockholders Equity | $7.34M | $14.92M | $28.06M | $40.58M | $1.78M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $7.34M | $14.92M | $28.06M | $40.58M | $1.78M |
| Total Investments | $- | $- | $16.81M | $- | $- |
| Total Debt | $84.16K | $175.05K | $80.49K | $169.33K | $- |
| Net Debt | $-5.70M | $-13.19M | $-9.55M | $-38.96M | $-1.64M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $5.79M | $7.38M | $7.30M | $9.74M | $13.36M | $15.96M | $12.70M | $6.81M | $9.63M | $6.72M | $14.26M | $33.22M | $39.13M | $41.86M | $16.99M | $4.49M | $1.64M | $17.08M | $13.80M | $-3.80M |
| Short Term Investments | $- | $- | $- | $- | $- | $- | $6.99M | $14.88M | $16.81M | $21.74M | $18.75M | $2.96M | $- | $44.45K | $- | $- | $- | $- | $- | $7.60M |
| Cash and Short Term Investments | $5.79M | $7.38M | $7.30M | $9.74M | $13.36M | $15.96M | $19.69M | $21.68M | $26.43M | $28.46M | $33.01M | $36.18M | $39.13M | $41.86M | $16.99M | $4.49M | $1.64M | $17.08M | $13.80M | $3.80M |
| Net Receivables | $- | $- | $- | $- | $- | $- | $- | $19.06K | $- | $- | $- | $- | $21.06K | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $-19.06K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Current Assets | $831.58K | $248.74K | $186.73K | $551.03K | $650.47K | $898.98K | $212.88K | $451.69K | $892.34K | $1.13M | $260.88K | $820.30K | $1.23M | $2.00M | $1.80M | $809.37K | $94.50K | $609.00K | $1.31M | $- |
| Total Current Assets | $6.62M | $7.63M | $7.49M | $10.29M | $14.00M | $16.84M | $19.87M | $22.15M | $27.24M | $29.59M | $33.27M | $36.92M | $40.39M | $43.85M | $18.79M | $5.30M | $1.73M | $17.68M | $15.11M | $3.80M |
| Property Plant Equipment Net | $82.17K | $105.66K | $128.63K | $151.12K | $173.94K | $195.81K | $217.22K | $238.20K | $81.31K | $104.59K | $127.58K | $150.37K | $172.89K | $4.33K | $3.12K | $1.14K | $1.35K | $2.63M | $2.96M | $- |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $638.25K | $504.73K | $504.73K | $504.73K | $754.73K | $754.73K | $754.73K | $754.73K | $738.25K | $754.73K | $659.05K | $16.48K | $16.48K | $- | $1.30M | $44.45K | $44.45K | $3.72M | $3.72M | $-3.80M |
| Total Non-Current Assets | $720.43K | $610.38K | $633.36K | $655.85K | $928.67K | $950.53K | $971.95K | $992.93K | $819.56K | $859.32K | $786.63K | $166.84K | $189.37K | $4.33K | $1.30M | $45.58K | $45.79K | $6.35M | $6.68M | $-3.80M |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $-0 | $0 | $-0 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Assets | $7.34M | $8.24M | $8.12M | $10.95M | $14.92M | $17.79M | $20.84M | $23.14M | $28.06M | $30.45M | $34.06M | $37.09M | $40.58M | $43.86M | $20.09M | $5.34M | $1.78M | $24.04M | $21.78M | $- |
| Account Payables | $870.23K | $555.95K | $416.56K | $405.46K | $806.00K | $617.27K | $747.67K | $382.10K | $1.38M | $1.25M | $2.43M | $2.83M | $2.64M | $3.34M | $397.00K | $75.56K | $155.96K | $531.00K | $382.00K | $- |
| Short Term Debt | $84.16K | $103.98K | $206.45K | $204.93K | $203.41K | $202.01K | $200.84K | $99.84K | $160.99K | $197.25K | $195.81K | $194.37K | $96.47K | $- | $630.00K | $- | $- | $558.00K | $532.00K | $- |
| Tax Payables | $- | $- | $20.00K | $50.00K | $40.00K | $30.00K | $20.00K | $50.00K | $128.93K | $96.70K | $64.47K | $50.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $-617.27K | $-747.67K | $-1.72M | $- | $- | $-97.91K | $- | $- | $- | $- | $-581.00K | $145.94K | $- | $- | $- |
| Other Current Liabilities | $2.44M | $1.57M | $1.29M | $876.91K | $1.72M | $1.52M | $1.13M | $1.29M | $1.77M | $1.34M | $930.92K | $600.60K | $1.87M | $2.44M | $4.41M | $6.10M | $1.86M | $3.46M | $3.46M | $- |
| Total Current Liabilities | $3.39M | $2.23M | $1.93M | $1.54M | $2.77M | $2.37M | $2.10M | $1.82M | $3.43M | $2.88M | $3.62M | $3.68M | $4.60M | $5.78M | $5.44M | $6.17M | $2.02M | $4.55M | $4.38M | $- |
| Long Term Debt | $- | $4.01K | $27.58K | $50.66K | $73.35K | $95.24K | $116.17K | $136.67K | $- | $4.95K | $27.91K | $50.52K | $72.86K | $- | $- | $356.00K | $- | $458.00K | $536.00K | $647.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $716.00K | $527.00K | $- | $951.00K | $690.00K | $-647.00K |
| Total Non-Current Liabilities | $- | $4.01K | $27.58K | $50.66K | $73.35K | $95.24K | $116.17K | $136.67K | $1.46M | $4.95K | $27.91K | $50.52K | $72.86K | $- | $716.00K | $883.00K | $72.86K | $1.41M | $1.23M | $- |
| Other Liabilities | $- | $- | $- | $1 | $- | $- | $- | $- | $-1.46M | $- | $- | $- | $- | $- | $- | $-883.00K | $-72.86K | $1 | $- | $- |
| Total Liabilities | $3.39M | $2.24M | $1.96M | $1.59M | $2.85M | $2.46M | $2.22M | $1.96M | $3.43M | $2.89M | $3.65M | $3.73M | $4.68M | $5.78M | $6.16M | $6.17M | $2.02M | $5.96M | $5.61M | $- |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $315 | $315 | $8.36K | $- | $- | $315 |
| Common Stock | $120.14K | $101.97K | $85.53K | $85.39K | $84.01K | $84.01K | $84.01K | $84.01K | $84.01K | $82.59K | $82.59K | $82.59K | $82.59K | $81.33K | $727.00K | $733 | $19.45K | $727.00K | $727.00K | $- |
| Retained Earnings | $-60.44M | $-56.31M | $-53.24M | $-49.22M | $-45.42M | $-41.41M | $-37.49M | $-34.25M | $-29.99M | $-26.34M | $-22.87M | $-19.04M | $-15.67M | $-12.45M | $-215.21M | $-8.57M | $-7.96M | $-199.98M | $-196.24M | $- |
| Accumulated Other Comprehensive Income Loss | $- | $- | $- | $- | $-0 | $-0 | $134.16K | $177.46K | $96.43K | $15.13K | $-26.94K | $-9.22K | $- | $-0 | $-315 | $0 | $-43.79M | $- | $- | $3.21M |
| Other Total Stockholders Equity | $64.26M | $62.21M | $59.32M | $58.50M | $57.41M | $56.66M | $55.90M | $55.17M | $54.44M | $53.81M | $53.22M | $52.32M | $51.49M | $50.45M | $228.42M | $7.74M | $7.69M | $217.33M | $211.69M | $- |
| Total Stockholders Equity | $3.94M | $6.00M | $6.17M | $9.36M | $12.08M | $15.33M | $18.63M | $21.19M | $24.63M | $27.57M | $30.41M | $33.36M | $35.90M | $38.08M | $13.94M | $-829.68K | $-237.70K | $18.08M | $16.18M | $3.21M |
| Total Equity | $3.94M | $6.00M | $6.17M | $9.36M | $12.08M | $15.33M | $18.63M | $21.19M | $24.63M | $27.57M | $30.41M | $33.36M | $35.90M | $38.08M | $13.94M | $-829.68K | $-237.70K | $18.08M | $16.18M | $3.21M |
| Total Liabilities and Stockholders Equity | $7.34M | $8.24M | $8.12M | $10.95M | $14.92M | $17.79M | $20.84M | $23.14M | $28.06M | $30.45M | $34.06M | $37.09M | $40.58M | $43.86M | $20.09M | $5.34M | $1.78M | $24.04M | $21.78M | $3.21M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $7.34M | $8.24M | $8.12M | $10.95M | $14.92M | $17.79M | $20.84M | $23.14M | $28.06M | $30.45M | $34.06M | $37.09M | $40.58M | $43.86M | $20.09M | $5.34M | $1.78M | $24.04M | $21.78M | $3.21M |
| Total Investments | $- | $- | $- | $- | $- | $- | $6.99M | $14.88M | $16.81M | $21.74M | $18.75M | $2.96M | $- | $44.45K | $- | $- | $- | $- | $- | $7.60M |
| Total Debt | $84.16K | $107.99K | $130.80K | $153.13K | $175.05K | $196.24K | $216.59K | $236.51K | $80.49K | $103.57K | $125.81K | $147.70K | $169.33K | $- | $630.00K | $178.00K | $169.33K | $558.00K | $532.00K | $- |
| Net Debt | $-5.70M | $-7.27M | $-7.17M | $-9.59M | $-13.19M | $-15.77M | $-12.48M | $-6.57M | $-9.55M | $-6.61M | $-14.13M | $-33.07M | $-38.96M | $-41.86M | $-16.36M | $-4.31M | $-1.47M | $-16.52M | $-13.27M | $3.80M |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-15.02M | $-15.42M | $-14.32M | $-7.71M | $-3.58M |
| Depreciation and Amortization | $735 | $1.28K | $1.78K | $1.40K | $852 |
| Deferred Income Tax | $- | $- | $- | $-5.75M | $3.36M |
| Stock Based Compensation | $2.31M | $2.97M | $2.96M | $1.51M | $139.96K |
| Change in Working Capital | $392.25K | $-518.07K | $-1.58M | $-5.09M | $118.71K |
| Accounts Receivables | $- | $- | $- | $- | $3.39M |
| Inventory | $- | $- | $- | $- | $-3.39M |
| Accounts Payables | $474.06K | $-680.52K | $-1.15M | $-4.24M | $113.90K |
| Other Working Capital | $-81.80K | $162.45K | $-425.59K | $-854.15K | $4.81K |
| Other Non Cash Items | $- | $-430.99K | $-134.16K | $5.75M | $-3.36M |
| Net Cash Provided by Operating Activities | $-12.32M | $-13.41M | $-13.08M | $-11.29M | $-3.32M |
| Investments in Property Plant and Equipment | $- | $- | $-172.56K | $-3.85K | $- |
| Acquisitions Net | $- | $- | $172.56K | $451.60K | $- |
| Purchases of Investments | $- | $-6.86M | $-29.60M | $- | $- |
| Sales Maturities of Investments | $- | $24.00M | $13.00M | $- | $- |
| Other Investing Activities | $- | $- | $172.56K | $451.60K | $- |
| Net Cash Used for Investing Activities | $- | $17.14M | $-16.43M | $447.75K | $- |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $5.51M | $- | $- | $5.00M | $1.16M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $-762.70K | $- | $- | $43.34M | $- |
| Net Cash Used Provided by Financing Activities | $4.75M | $- | $- | $48.34M | $1.16M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $-7.58M | $3.74M | $-29.51M | $37.49M | $-2.16M |
| Cash at End of Period | $5.79M | $13.36M | $9.63M | $39.13M | $1.64M |
| Cash at Beginning of Period | $13.36M | $9.63M | $39.13M | $1.64M | $3.80M |
| Operating Cash Flow | $-12.32M | $-13.41M | $-13.08M | $-11.29M | $-3.32M |
| Capital Expenditure | $- | $- | $-172.56K | $-3.85K | $- |
| Free Cash Flow | $-12.32M | $-13.41M | $-13.25M | $-11.29M | $-3.32M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-4.13M | $-3.07M | $-4.02M | $-3.81M | $-4.00M | $-3.92M | $-3.25M | $-4.25M | $-3.66M | $-3.47M | $-3.84M | $-3.37M | $-3.22M | $7.17M | $-11.05M | $-612.42K | $-770.22K | $4.00M | $-713 | $-559 |
| Depreciation and Amortization | $- | $- | $- | $735 | $320 | $321 | $322 | $321 | $321 | $392 | $534 | $534 | $535 | $-1.18M | $1.18M | $213 | $213 | $-610.36K | $0 | $0 |
| Deferred Income Tax | $- | $- | $- | $- | $1.05M | $- | $567.27K | $- | $- | $- | $- | $- | $10.53M | $-10.53M | $- | $- | $- | $-5.55M | $- | $- |
| Stock Based Compensation | $304.12K | $444.18K | $782.85K | $774.69K | $745.52K | $764.80K | $728.47K | $727.14K | $637.63K | $584.04K | $904.39K | $831.18K | $673.80K | $628.46K | $187.56K | $20.45K | $23.09K | $-739.13K | $39 | $39 |
| Change in Working Capital | $431.18K | $111.82K | $754.46K | $-905.21K | $636.19K | $-436.56K | $570.72K | $-1.31M | $909.08K | $-1.71M | $-217.59K | $-560.14K | $-997.73K | $-3.69M | $-173.18K | $-233.82K | $-210.11K | $1.83M | $13 | $52 |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $222.15K | $-727.00K | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $1.15M | $173.67K | $396.94K | $-1.24M | $397.82K | $261.44K | $280.00K | $-1.63M | $570.76K | $-743.95K | $-56.44K | $-925.20K | $-1.27M | $-3.06M | $188.12K | $481.05K | $-234.34K | $- | $- | $- |
| Other Working Capital | $-716.71K | $-61.85K | $357.52K | $332.29K | $238.37K | $-698.00K | $290.71K | $323.00K | $338.32K | $-967.83K | $360 | $365.07K | $274.78K | $-1.16M | $11.04K | $-714.87K | $24.23K | $1.83M | $13 | $52 |
| Other Non Cash Items | $- | $- | $- | $2.01M | $-1.03M | $-140.57K | $-728.47K | $-129.23K | $-102.17K | $-7.84K | $-56 | $-24.16K | $-10.53M | $7.25M | $3.29M | $2.12M | $-234 | $5.51M | $-156 | $55 |
| Net Cash Provided by Operating Activities | $-3.40M | $-2.51M | $-2.48M | $-3.94M | $-2.60M | $-3.73M | $-2.11M | $-4.96M | $-2.21M | $-4.60M | $-3.15M | $-3.12M | $-3.54M | $-353.82K | $-6.57M | $-825.58K | $-957.03K | $4.45M | $-817 | $-413 |
| Investments in Property Plant and Equipment | $- | $- | $- | $- | $- | $- | $- | $- | $-3.94K | $-1.94M | $2.97M | $-2.97M | $3.85K | $-3.85K | $1.00K | $-1.00K | $- | $3.00K | $- | $- |
| Acquisitions Net | $- | $- | $- | $- | $- | $- | $- | $- | $-1.18K | $-1.35K | $-3.89K | $172.56K | $462.47K | $- | $- | $- | $- | $- | $- | $- |
| Purchases of Investments | $- | $- | $- | $- | $24.44K | $106.02K | $110.23K | $-6.86M | $-5.88M | $-4.94M | $-15.81M | $-2.97M | $- | $- | $- | $- | $- | $- | $- | $- |
| Sales Maturities of Investments | $- | $- | $- | $- | $-85.53K | $7.00M | $8.00M | $9.00M | $11.00M | $1.94M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Investing Activities | $- | $- | $- | $- | $61.08K | $-106.02K | $-110.23K | $2.14K | $5.12K | $2.00M | $-15.81K | $172.56K | $447.75K | $- | $- | $- | $- | $-772.00K | $- | $- |
| Net Cash Used for Investing Activities | $- | $- | $- | $- | $-61.08K | $7.00M | $8.00M | $2.14M | $5.12M | $-2.94M | $-15.81M | $-2.80M | $451.60K | $-3.85K | $1.00K | $-1.00K | $- | $-769.00K | $- | $- |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $2.14M | $3.00M | $39.54K | $336.04K | $- | $- | $- | $- | $- | $- | $- | $- | $1.23M | $-4.90M | $9.92M | $3.67M | $-3.96K | $-9.37M | $- | $- |
| Common Stock Repurchased | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $-333.19K | $-408.04K | $-1.48K | $-20.00K | $- | $- | $- | $- | $- | $- | $- | $- | $363.06K | $42.02M | $1.77M | $3.67M | $-3.96K | $-65.00K | $35 | $1.13K |
| Net Cash Used Provided by Financing Activities | $1.80M | $2.59M | $38.06K | $316.05K | $- | $- | $- | $- | $- | $- | $- | $- | $363.06K | $37.12M | $7.18M | $3.67M | $-3.96K | $-9.44M | $35 | $1.13K |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-12.89M | $- | $1.00K | $- | $-5.44M | $- | $- |
| Net Change in Cash | $-1.59M | $78.94K | $-2.44M | $-3.62M | $-2.60M | $3.27M | $5.89M | $-2.82M | $2.91M | $-7.54M | $-18.96M | $-5.92M | $-2.73M | $23.87M | $13.50M | $2.85M | $-960.99K | $-11.20M | $-782 | $719 |
| Cash at End of Period | $5.79M | $7.38M | $7.30M | $9.74M | $13.36M | $15.96M | $12.70M | $6.81M | $9.63M | $6.72M | $14.26M | $33.22M | $39.13M | $41.86M | $17.99M | $4.49M | $1.64M | $2.60M | $3.74K | $4.52K |
| Cash at Beginning of Period | $7.38M | $7.30M | $9.74M | $13.36M | $15.96M | $12.70M | $6.81M | $9.63M | $6.72M | $14.26M | $33.22M | $39.13M | $41.86M | $17.99M | $4.49M | $1.64M | $2.60M | $13.80M | $4.52K | $3.80K |
| Operating Cash Flow | $-3.40M | $-2.51M | $-2.48M | $-3.94M | $-2.60M | $-3.73M | $-2.11M | $-4.96M | $-2.21M | $-4.60M | $-3.15M | $-3.12M | $-3.54M | $-353.82K | $-6.57M | $-825.58K | $-957.03K | $4.45M | $-817 | $-413 |
| Capital Expenditure | $- | $- | $- | $- | $- | $- | $- | $- | $-3.94K | $-1.94M | $2.97M | $-2.97M | $3.85K | $-3.85K | $1.00K | $-1.00K | $- | $3.00K | $- | $- |
| Free Cash Flow | $-3.40M | $-2.51M | $-2.48M | $-3.94M | $-2.60M | $-3.73M | $-2.11M | $-4.96M | $-2.21M | $-6.54M | $-177.48K | $-6.09M | $-3.54M | $-357.67K | $-6.57M | $-826.58K | $-957.03K | $4.45M | $-817 | $-413 |
Indaptus Therapeutics Dividends
Explore Indaptus Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Indaptus Therapeutics News
Read the latest news about Indaptus Therapeutics, including recent articles, headlines, and updates.
Indaptus Therapeutics Chief Medical Officer Roger Waltzman, M.D., M.B.A. to Moderate Panel at CMO360 Summit
NEW YORK, March 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company pioneering innovative therapies for cancer and viral infections, announces that its chief medical officer, Roger Waltzman, M.D., M.B.A. will be moderating a panel at the annual CMO360 Summit, being held April 7-8 in Boston.
Indaptus Therapeutics Reports New Data Demonstrating Successful Broad Immune System Activation in Weekly Dosing Trial of Decoy20
NEW YORK, March 20, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today provided an update on key pharmacodynamic findings from the weekly dosing cohort of its ongoing Phase 1 trial of Decoy20. As announced in last week's earnings release, the Company has now enrolled more than 20 patients in the weekly dosing cohort, marking a key milestone in the trial.
Indaptus Therapeutics Initiates Phase 1 Combination Study of Decoy20 with PD-1 Checkpoint Inhibitor Tislelizumab
NEW YORK, March 18, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that it has advanced to a new expansion arm of its Phase 1b/2 clinical trial of Decoy20. This expansion will evaluate the combination of Decoy20 with BeiGene's PD-1 checkpoint inhibitor, tislelizumab, with a focus on safety, dose optimization, and early signs of anti-tumor activity.
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2024 Financial Results and Provides Corporate Update
NEW YORK, March 13, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announces financial results for the fourth quarter and fiscal year ended December 31, 2024 and provides a corporate update.
Registration Is Now Open For Tribe Public's Webinar Event “Keys To The Kingdom: Unlocking The Power Of Your Immune System” Featuring Indaptus Therapeutics' CEO On Monday, March 17, 2025
NEW YORK, March 12, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus' CEO, Jeffrey Meckler, will present at Tribe Public's Webinar Presentation and Q&A Event titled “Keys To The Kingdom: Unlocking The Power Of Your Immune System.” The Event is scheduled to begin at 9:00am pacific/12:00pm eastern on Monday, March 17, 2025. To register to join the complimentary event, please visit the Tribe Public LLC at INDP-KEYS.TribePublic.com .
Indaptus Therapeutics Expands Patent Portfolio in China, Japan, and Israel, Strengthening its Intellectual Property for Infectious Disease and Cancer Treatments
NEW YORK, March 04, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, announced today that it has secured new patent approvals in China, Japan and Israel for its Decoy platform. These patents cover the use of Decoy bacteria compositions for preventing or treating Hepatitis B virus (HBV) and human immunodeficiency virus (HIV) – two diseases that continue to pose major global health challenges. The patents also extend to combination therapies with a variety of both approved and investigational treatments.
Indaptus Therapeutics' Chief Scientific Officer Dr. Michael Newman to Present at the 10th Annual Innate Killer Summit
NEW YORK, Feb. 25, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical-stage biotechnology company dedicated to developing novel treatments for cancer and viral infections, today announced that Michael Newman, Founder and Chief Scientific Officer, will present at the 10th Annual Innate Killer Summit, taking place from March 3-5, 2025, in San Diego, California. Dr. Newman will deliver a scientific presentation on Tuesday, March 4, 2025, titled, “Employing Attenuated & Killed Gram-Negative Bacteria to Induce NK-Mediated Anti-Tumor Immunity.
Indaptus Therapeutics Receives Approval from Health Canada to Expand Clinical Trial of Decoy20
NEW YORK, Feb. 05, 2025 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical-stage biotechnology company pioneering innovative cancer and viral infection treatments, today announced the Company has received Clinical Trial Authorization from Health Canada to initiate its clinical trial for its lead asset, Decoy20. This approval will allow the Company to expand its ongoing U.S. clinical trial, INDP-D101, to Canadian sites, broadening patient recruitment and enhancing its clinical research program. The trial will enroll patients in Canada under the current protocol, which involves weekly dosing of Decoy20. Indaptus also plans to submit an amendment to Health Canada to incorporate its upcoming combination trial, which pairs Decoy20 with Beigene's PD-1 checkpoint inhibitor, tislelizumab.
Indaptus Therapeutics, Inc. Announces $2.135 Million Registered Direct Offering and Concurrent Private Placement
NEW YORK, Nov. 22, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, today announced that it has entered into securities purchase agreements with investors, including an officer of Indaptus, for the issuance and sale of an aggregate of 1,817,017 of its shares of common stock. In a concurrent private placement, Indaptus has also agreed to issue and sell unregistered warrants to purchase up to an aggregate of 1,817,017 of its shares of common stock. The combined effective purchase price for each share of common stock and associated warrants is $1.175. The warrants will have an exercise price of $1.05 per share, will be immediately exercisable upon issuance and have a term of five years from the date of issuance. The closing of the offering is expected to take place on or about November 25, 2024, subject to the satisfaction of customary closing conditions.
Indaptus Therapeutics' Pioneering Research on Novel Immunotherapy Approach Published in Peer-Reviewed Frontiers in Immunology
Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapy Preclinical data demonstrates Decoy platform single agent anti-tumor activity and combination-mediated tumor eradication with NSAID, anti-PD1 checkpoint therapy, low dose chemotherapy (LDC) and/or targeted antibody therapy
Indaptus Therapeutics Presents Encouraging Interim Safety Data from Phase 1 Clinical Trial of Decoy20 at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting
NEW YORK, Nov. 07, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, announces compelling safety, pharmacokinetics, and biomarker data on its lead compound, Decoy20, at the Society for Immunotherapy of Cancer (SITC) 2024 annual meeting. The data derive from two cohorts (13 patients) of Decoy20 single administration and one cohort (6 patients) of Decoy20 weekly administration in the Company's ongoing Phase 1 clinical trial.
Indaptus Therapeutics Reports First Quarter 2024 Financial Results and Provides Corporate Update
Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20 Company to present poster at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2024 highlighting initial results from its Phase 1 clinical trial of Decoy20
Indaptus Therapeutics Presents Positive Mechanism of Action Data at the American Association for Cancer Research Annual Meeting
Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly Results Indicate Decoy Platform Broadly Boosts Immune System's Ability to Fight Tumors Directly and Indirectly
Indaptus Therapeutics Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the fourth quarter and fiscal year ended December 31, 2023 and provided a corporate update.
Indaptus Therapeutics Expands Digital Presence with Launch of Social Media Channels
NEW YORK, Feb. 08, 2024 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a clinical stage biotechnology company dedicated to pioneering innovative cancer and viral infection treatments, is pleased to announce the launch of a new social media initiative to provide education and updates about the company. Recognizing the importance of engaging with all stakeholders, Indaptus will generate content on a variety of digital platforms, including X (formerly known as Twitter) and LinkedIn.
European Patent Office Approves Key Patent for Indaptus Therapeutics' Platform Technology
Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza Patent will provide additional protection covering a composition targeting any viral infection, including hepatitis B, HIV, and influenza
Indaptus Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Nov. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the third quarter ended September 30, 2023 and provided a corporate update.
Indaptus Therapeutics to Present Positive Pharmacodynamic (PD) Immune and Pharmacokinetic (PK) Results with Patients from First Cohort of Ongoing Phase 1 Study of Decoy20 at Cancer Immunotherapy Meeting
Poster to be presented at 38 th Annual Meeting of the Society for Immunotherapy of Cancer on November 4 , 2023
Registration Is Now Open For Tribe Public's Webinar Event "Immunotherapy Reimagined" Featuring Indaptus Therapeutics' CEO On Friday, September 29, 2023
NEW YORK, Sept. 26, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (NASDAQ: INDP) announces that Indaptus' CEO, Jeffrey Meckler will present at Tribe Public's Webinar Presentation and Q&A Event titled “Immunotherapy Reimagined.
Indaptus Therapeutics to Present at the H.C. Wainwright 25th Annual Global Investment Conference
NEW YORK, Sept. 06, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) announced today that Jeffrey A. Meckler, Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 25th Annual Global Investment Conference. The conference is being held on September 11 – 13, 2023 at the Lotte New York Palace Hotel.
Indaptus Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update
NEW YORK, Aug. 14, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced financial results for the second quarter ended June 30, 2023 and provided a corporate update.
Indaptus Therapeutics Announces Opening of Next Cohort in Single Dose Ranging Study of Decoy20
NEW YORK, Aug. 10, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP) (“Indaptus” or the “Company”) today announced completion of the first cohort of patients who received a single dose in Part 1 of its INDP-D101 trial of Decoy20 and the initiation of a new cohort following review of data by the Safety Review Committee as prescribed by the clinical trial protocol.
Indaptus Therapeutics Appoints Industry Veteran Roger Waltzman, M.D. Chief Medical Officer
NEW YORK, Aug. 07, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, announces the appointment of Roger Waltzman, M.D. as its Chief Medical Officer, effective August 7, 2023.
Indaptus Therapeutics to Present at the Planet MicroCap Showcase: VEGAS 2023
NEW YORK, April 20, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that CEO Jeffrey A. Meckler will present a corporate overview at the Planet MicroCap Showcase: VEGAS 2023. The conference is being held on April 25 – 27, 2023 at the Horseshoe Hotel & Casino (formerly Bally's) in Las Vegas, NV.
Indaptus Therapeutics to Present at the Investor Summit Conference
NEW YORK, March 22, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that it will participate at the Investor Summit Conference being held virtually on March 29, 2023.
Indaptus Therapeutics to Present Poster on Its Decoy Anti-Tumor Platform at the American Association for Cancer Research Conference 2023
NEW YORK, March 15, 2023 (GLOBE NEWSWIRE) -- Indaptus Therapeutics, Inc. (Nasdaq: INDP, “Indaptus” or “the Company”), a biotechnology company focused on discovering and developing transformative therapeutics for patients, today announces that the American Association for Cancer Research (AACR) has accepted an abstract on its Decoy anti-tumor platform for its annual scientific conference on April 14-19, 2023 in Orlando.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for INDP.